BioRestorative Therapies Inc.
Last updated September 27, 2026
Organization details
- Legal name
- BioRestorative Therapies Inc.
- Former names
- Stem Cell Assurance, Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 8090 — Services-Misc Health & Allied Services, NEC
- Jurisdiction of incorporation
- Nevada
- Headquarters city
- Melville
- Headquarters state / province
- New York
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- BRTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001505497
- EIN
- 30-1341024
Board of directors
-
David A. Rosa · DirectorSince 2023
-
Esha Randhawa · DirectorSince 2026
-
Francisco Silva · Director · VP of Research and DevelopmentSince 2023
-
Jatinder Dhaliwal · DirectorSince 2026
-
Katharyn Field · DirectorSince 2026
-
Lance Alstodt · Director · President, CEO, COBSince 2023
-
Mika Grasso · DirectorSince 2026
-
Nickolay Kukekov V · DirectorSince 2023
-
Patrick F. Williams · DirectorSince 2023
-
Steven Collier Brown · DirectorSince 2026
Chief executives
Lance Alstodt
· President, CEO, COB
Dates unknown
Director election results
Annual meeting of September 18, 2025. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
88.5%
-
95.6%
Board connections
4 of this board's directors also sit on 6 other boards.
- via Katharyn Field and Mika Grasso
- via David A. Rosa
- via Jatinder Dhaliwal
- via Katharyn Field
- via David A. Rosa
- via Katharyn Field
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Oct 6, 2025 | Francisco Silva Director, Officer (VP of Research and Development) | Grant or award | +11,719 | $1.60 | $18,750 |
| Oct 6, 2025 | Lance Alstodt Director, Officer (President, CEO, COB), 10% owner | Grant or award | +15,625 | $1.60 | $25,000 |
| Oct 28, 2024 | Broadrick Dale 10% owner | Open-market sale | −1,112 | $1.58 | $1,757 |
| Apr 9, 2024 | Francisco Silva Director, Officer (VP of Research and Development) | Open-market purchase | +6,600 | $1.25 | $8,250 |
| Apr 8, 2024 | Francisco Silva Director, Officer (VP of Research and Development) | Open-market purchase | +476 | $1.13 | $538 |
| Apr 8, 2024 | Francisco Silva Director, Officer (VP of Research and Development) | Open-market purchase | +1,232 | $1.17 | $1,441 |
| Mar 18, 2024 | Francisco Silva Director, Officer (VP of Research and Development) | Shares withheld for tax | −17,193 | $1.39 | $23,898 |
| Mar 18, 2024 | Lance Alstodt Director, Officer (President, CEO, COB) | Shares withheld for tax | −17,633 | $1.39 | $24,510 |
| Feb 9, 2024 | Broadrick Dale 10% owner | Open-market purchase | +86,041 | $1.32 | $113,574 |
| Feb 8, 2024 | Broadrick Dale 10% owner | Open-market purchase | +73,959 | $1.25 | $92,449 |
| Feb 8, 2024 | Broadrick Dale 10% owner | Open-market purchase | +83,626 | $1.34 | $112,059 |
| Feb 7, 2024 | Broadrick Dale 10% owner | Open-market purchase | +36,374 | $1.38 | $50,196 |
| Dec 1, 2023 | Broadrick Dale 10% owner | Open-market sale | −250 | $1.88 | $470 |
| Nov 27, 2023 | Broadrick Dale 10% owner | Open-market sale | −278 | $1.89 | $525 |
| Sep 15, 2023 | Lance Alstodt Director, Officer (President, CEO, COB), 10% owner | Open-market purchase | +2,200 | $1.70 | $3,740 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.